COVID-19: State of the Vaccination

The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the resulting coronavirus disease 2019 (COVID-19) pandemic has led to rapid vaccine development and emergency use (EU) rollout. Six vaccines, including two using novel mRNA technology, are EU-listed by the World He...

Descripción completa

Detalles Bibliográficos
Autores principales: Fenton, Caroline, Lamb, Yvette N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Practical Issues and Updates
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517556/
https://www.ncbi.nlm.nih.gov/pubmed/34667427
http://dx.doi.org/10.1007/s40267-021-00869-4
_version_ 1784584045372375040
author Fenton, Caroline
Lamb, Yvette N.
author_facet Fenton, Caroline
Lamb, Yvette N.
author_sort Fenton, Caroline
collection PubMed
description The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the resulting coronavirus disease 2019 (COVID-19) pandemic has led to rapid vaccine development and emergency use (EU) rollout. Six vaccines, including two using novel mRNA technology, are EU-listed by the World Health Organisation, and promising published trial data are available for nine more. While efficacy is good, there are various barriers to their global use. Long-term safety and immunogenicity data are being collected along the way.
format Online
Article
Text
id pubmed-8517556
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-85175562021-10-15 COVID-19: State of the Vaccination Fenton, Caroline Lamb, Yvette N. Drugs Ther Perspect Practical Issues and Updates The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the resulting coronavirus disease 2019 (COVID-19) pandemic has led to rapid vaccine development and emergency use (EU) rollout. Six vaccines, including two using novel mRNA technology, are EU-listed by the World Health Organisation, and promising published trial data are available for nine more. While efficacy is good, there are various barriers to their global use. Long-term safety and immunogenicity data are being collected along the way. Springer International Publishing 2021-10-15 2021 /pmc/articles/PMC8517556/ /pubmed/34667427 http://dx.doi.org/10.1007/s40267-021-00869-4 Text en © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Practical Issues and Updates
Fenton, Caroline
Lamb, Yvette N.
COVID-19: State of the Vaccination
title COVID-19: State of the Vaccination
title_full COVID-19: State of the Vaccination
title_fullStr COVID-19: State of the Vaccination
title_full_unstemmed COVID-19: State of the Vaccination
title_short COVID-19: State of the Vaccination
title_sort covid-19: state of the vaccination
topic Practical Issues and Updates
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517556/
https://www.ncbi.nlm.nih.gov/pubmed/34667427
http://dx.doi.org/10.1007/s40267-021-00869-4
work_keys_str_mv AT fentoncaroline covid19stateofthevaccination
AT lambyvetten covid19stateofthevaccination

Ejemplares similares